

ENDO PHARMACEUTICALS HOLDINGS INC
 Form 4
 November 01, 2005

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 ENDO PHARMA LLC

2. Issuer Name and Ticker or Trading Symbol
 ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 320 PARK AVENUE
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)
 10/28/2005

____ Director
 ____ Officer (give title below)
 10% Owner
 ____ Other (specify below)

NEW YORK, NY 10022
 (City) (State) (Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				Code	V Amount (A) or (D) Price			
Common Stock, par value \$.01 per share	10/28/2005		X	700	D	\$ 2.42 21,847,827	D	
Common Stock, par value \$.01 per share	10/28/2005		X	4,274	D	\$ 2.42 21,843,553	D	
Common Stock, par value \$.01 per share	10/28/2005		X	21,860	D	\$ 2.42 21,821,693	D	

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Common Stock, par value \$.01 per share	10/28/2005	X	10,978	D	\$ 2.42	21,810,715	D
Common Stock, par value \$.01 per share	10/28/2005	X	18,869	D	\$ 2.42	21,791,846	D
Common Stock, par value \$.01 per share	10/28/2005	X	960	D	\$ 2.42	21,790,886	D
Common Stock, par value \$.01 per share	10/28/2005	X	19,479	D	\$ 3	21,771,407	D
Common Stock, par value \$.01 per share	10/28/2005	X	4,102	D	\$ 3	21,767,305	D
Common Stock, par value \$.01 per share	10/28/2005	X	14,707	D	\$ 3	21,752,598	D
Common Stock, par value \$.01 per share	10/28/2005	X	12,285	D	\$ 3.42	21,740,313	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number

									of Share
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	700	10/13/2005	08/26/2007	Common Stock	700	
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	4,274	10/13/2005	08/26/2007	Common Stock	4,274	
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	21,860	10/13/2005	08/26/2007	Common Stock	21,860	
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	10,978	10/13/2005	08/26/2007	Common Stock	10,978	
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	18,869	10/13/2005	08/26/2007	Common Stock	18,869	
Call Option (obligation to sell)	\$ 2.42	10/28/2005	X	960	10/13/2005	08/26/2007	Common Stock	960	
Call Option (obligation to sell)	\$ 3	10/28/2005	X	19,479	10/13/2005	08/26/2007	Common Stock	19,479	
Call Option (obligation to sell)	\$ 3	10/28/2005	X	4,102	10/13/2005	08/26/2007	Common Stock	4,102	
Call Option (obligation to sell)	\$ 3	10/28/2005	X	14,707	10/13/2005	08/26/2007	Common Stock	14,707	
Call Option (obligation to sell)	\$ 3.42	10/28/2005	X	12,285	10/13/2005	08/26/2007	Common Stock	12,285	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022		X		

Signatures

/s/ Jeffrey R. Black Chief Financial
Officer

11/01/2005

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.